Ranimustine (INN marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera.It has never been filed for FDA evaluation in the United States where it is not marketed.
This page contains content from the copyrighted Wikipedia article "Ranimustine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
